Ruella Lab
@RuellaLab
Followers
148
Following
2
Media
1
Statuses
6
We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella
Philadelphia, PA
Joined December 2019
New @NatureProtocols out!📢.An optimized workflow to generate gene-edited murine CAR T cells for immune-competent models, advancing studies of CAR T biology in native TME. Congrats @PuneethGuru_ @MarcoRuella @ranjani_52 @AlbertoCarturan @Shan_Liu_.
0
2
13
RT @JExpMed: .@puneeth_guru et al. @RuellaLab discuss the current landscape of single-cell transcriptomics for cancer #immunotherapy. https….
0
6
0
RT @MarcoRuella: Our letter to the @NEJM reporting the five-year outcomes of CART19 (CTL019, now called tisagenlecleucel) in lymphoma patie….
nejm.org
Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total of 60% of patients remained in remission at 5 years...
0
30
0
RT @MarcoRuella: Our latest review on single-cell RNAseq in immunotherapy is out in @JExpMed! Thanks for this Herculean endeavour to @punee….
0
16
0
RT @JExpMed: This review by @puneeth_guru, @MarcoRuella et al. @RuellaLab @PennMedicine examines how single-cell RNA sequencing has transfo….
0
25
0
Dr. Ruella will be speaking at the Advances in Adoptive Cell Therapies sponsored by BD Sciences! See link below for more information on the fantastic line up! . ↓↓↓.
0
0
0